Medifast (NYSE:MED) Director Parsa Kiai Acquires 4,329 Shares

Medifast Inc (NYSE:MED) Director Parsa Kiai acquired 4,329 shares of Medifast stock in a transaction on Monday, August 24th. The stock was purchased at an average price of $12.00 per share, with a total value of $51,948.00. Following the purchase, the director owned 665,517 shares of the company’s stock, valued at $7,986,204. The trade was a 0.65% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai bought 43,150 shares of Medifast stock. The stock was acquired at an average cost of $11.60 per share, for a total transaction of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai purchased 29,337 shares of Medifast stock. The stock was acquired at an average price of $11.66 per share, with a total value of $342,069.42.

Medifast Price Performance

Shares of NYSE:MED opened at $12.26 on Thursday. Medifast Inc has a 1-year low of $9.22 and a 1-year high of $14.67. The stock has a market cap of $137.07 million, a P/E ratio of -5.26 and a beta of 0.65. The firm has a fifty day moving average price of $10.96 and a 200 day moving average price of $11.08.

Medifast (NYSE:MED) last announced its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The business had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Sell-side analysts expect that Medifast Inc will post -1.04 EPS for the current fiscal year.

Institutional Trading of Medifast

A number of institutional investors have recently bought and sold shares of the company. Chico Wealth RIA purchased a new stake in Medifast in the 2nd quarter valued at approximately $223,000. Ancora Advisors LLC acquired a new position in Medifast in the second quarter valued at $75,000. Empowered Funds LLC purchased a new position in Medifast during the second quarter worth about $701,000. Bank of America Corp DE purchased a new stake in Medifast in the 2nd quarter valued at about $924,000. Finally, PDT Partners LLC purchased a new position in shares of Medifast during the 2nd quarter worth about $348,000. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Weiss Ratings raised shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. Zacks Research downgraded shares of Medifast from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $12.00.

Medifast News Roundup

Here are the key news stories impacting Medifast this week:

• Positive Sentiment: GLP-1 and metabolic-health opportunity: Medifast’s Trilivy launch represents a strategic shift toward metabolic health, supported by a 10-year roadmap and a focus on the expanding GLP-1 treatment market. Investors may view this as a potential long-term growth avenue as weight-loss and metabolic-health treatments gain adoption. Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
• Positive Sentiment: Insider buying: Director Parsa Kiai purchased 4,329 shares for approximately $51,948 at an average price of $12.00, increasing his direct holdings to 665,517 shares. The purchase may signal confidence in Medifast’s turnaround prospects and provides a modest supportive signal for the stock. Medifast Director Insider Transaction
• Positive Sentiment: More favorable earnings forecasts: Zacks Research raised its FY2026 EPS forecast to a loss of $1.04 from a loss of $1.97, FY2027 to a loss of $0.47 from $1.89, and FY2028 to a loss of $0.43 from $1.81. Several quarterly estimates were also sharply improved, suggesting analysts expect losses to narrow faster than previously anticipated. Medifast Rating Upgrade to Buy
• Neutral Sentiment: Rating upgrade: Zacks upgraded Medifast to Rank #2 (Buy), reflecting greater optimism about earnings prospects. However, Zacks Research separately maintains a “Hold” rating, indicating that analyst conviction remains mixed. Medifast Rating Upgrade to Buy
• Negative Sentiment: Profitability remains weak: Medifast is still expected to report losses, with consensus estimates near a $1.00 per-share loss for the current fiscal year. Its latest reported quarter also showed a negative EPS, net margin and return on equity, limiting the near-term fundamental support for the shares.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.